



Prevalence of *Helicobacter pylori* in Egypt: An over estimation or an iceberg?

Mohamed Alborai

Affiliations:

Department of Internal Medicine,
Al-Azhar University, Cairo 11884,
Egypt

Correspondence

Mohamed Alborai,
Department of Internal Medicine,
Al-Azhar University, Cairo,
Egypt
Email: alborai@azhar.edu.eg

Helicobacter pylori (*H. pylori*) is a prevalent infection that annoy both infected individuals and treating physicians. It can be detected in most of patients with upper gastrointestinal symptoms in areas of high prevalence (1).

To manage *H. pylori* appropriately, we need to know its actual prevalence, accuracy of diagnostic strategies, efficacy of treatments available and patterns of resistance to used antibiotics (2). In Egypt, the actual prevalence is not known due to lack of properly designed epidemiological studies about *H. pylori*. Several sporadic trials were published about *H. pylori* prevalence in specific populations (Table 1).

The prevalence of *H. pylori* in Egypt ranges from (13% - 90.9%) depending on the studied population and the year of publication. The prevalence in pediatric population ranges from 13%-72% and in adults from 26.2-90.9%. Average prevalence in pediatric population is about 44.4 % while average prevalence in adult population is about 67% and average prevalence in the whole population is about 62.5% . Table 1 and table 2 show reported data about *H. pylori* prevalence in different age groups and different clinical presentations.

It is crucial to keep in mind the precautions needed before testing for *H. pylori* as most diagnostics depend on bacterial viability (except serological test) and patients have to stop antibiotics at least 4 weeks before doing the test and they have also to stop acid suppressants like proton pump inhibitors (or potassium competitive acid blockers) one-two weeks before doing the test.

Due to this marked variability in reported prevalence and the heterogeneity of the studied population; it is of great importance to have a well-designed epidemiological study to accurately estimate the average prevalence of *H. pylori* in Egypt. This study should consider both symptomatic and asymptomatic population, different geographic regions, gender, and age groups. Based on the results of such well-designed prevalence study the actual prevalence could be estimated and further actions like disease burden, required diagnostics, complication rates, treatment costs, screening and prevention could be initiated on a solid base.

Table 1: Prevalence of *Helicobacter pylori* in adult population in Egypt

Clinical Context	Diagnostic test	Prevalence	Reference/ year
Chronic HCV	Stool antigen	88.3%	Hanafy et al. 2016 (3)
Dyspepsia	polymerase chain reaction/restricted fragment length on gastric biopsies	70%	Ghaith et al. 2016 (4)
GI Symptoms	Stool antigen	69.4%	Sabah et al. 2015 (5)
Pregnant women with pre eclampsia	Serology	54.4%	Mosbah & Nabil; 2015 (6)
Relatives of infected children	Serology	69.1%	Hamed et al. 2013 (7)
T1DM	Serology	79%	El-Eshmawy MM et al. 2012 (8)
Healthy controls	Serology	51.2%	
HCV	Rapid urease testing	55.6%	El-Masry et al. 2010 (9)
Healthy controls	Rapid urease testing	39.4%	
Perforated DU	Rapid urease testing/histology/culture	84.8%	El-Nakeeb et al. 2009 (10)
DM	Serology	85%	Hamed et al. 2008 (11)
Healthy controls	Serology	76.7%	
Coronary artery disease	Serology	61.2%	Badran & Mahfouz. 2006 (12)
Healthy controls	Serology	26.2%	
Recurrent aphthous ulcerations	H. Pylori PCR	67%	Elsheikh & Mahfouz. 2005 (13)
Primary Sjogren's S	Serology	80.6%	El Miedany et al. 2005 (14)
Secondary Sjogren's S	Serology	71%	
CT disorders	Serology	60.9%	
Healthy controls	Serology	56.3%	
Gastric cancer	Histology	57.6%	El-Shahat 2005 (15)
Dyspepsia /liver cirrhosis	Histology	65.75%	Elshal et al. 2004 (16)
Chronic liver disease & dyspepsia	Serology	82.2	Abdel Mageed et al. 2004 (17)
	PCR	53.3%	
Cholecystectomy	Histology	69.6%	Gad Elhak et al. 2004 (18)
Dyspeptic patient	Rapid urease test	58%	El-Nasr et al. 2003 (19)
	Histology	52%	
Pregnant women	Serology	88%	Bassily et al. 1999 (20)
Chronic liver disease	Culture	40.45%	Omar et al. 1997 (21)
	Rapid urease test	67.3%	
Asymptomatic young adults	Serology	87.6%	Salem et al. 1993 (22)
Medical personnel	Serology	86%	Salem et al. 1993 (23)
Healthy controls		90.9%	

Table 2: Prevalence of *Helicobacter pylori* in pediatric population in Egypt

Clinical Context	Diagnostic test	Prevalence	Reference/ year
Infants and children with PHG	Histology	60%	Eskander et al. 2018 (24)
Recurrent abdominal pain	Serology	43.3%	Badr et al. 2012 (25)
Iron deficiency anemia	Serology and UBT	48%	Fayed et al. 2008 (26)
Schoolchildren	UBT	72.38%	Mohammad et al. 2008 (27)
NHL	serology	43.2%	El-Mahallawy et al. 2004 (28)
Children attending out patient department	Serology	50.5%	Omar et al. 2001 (29)
Newborns	Serology	13% (7-9 months) & 25% (18 months)	Bassily et al. 1999 (20)

Declarations: Nothing to declare

References:

- Agarwal PK, Badkur M, Agarwal R, Patel S. Prevalence of *Helicobacter pylori* infection in upper gastrointestinal tract disorders (dyspepsia) patients visiting outpatient department of a hospital of North India. *J Family Med Prim Care*. 2018;7(3):577-80.
- Saleem N, Howden CW. Update on the Management of *Helicobacter pylori* Infection. *Curr Treat Options Gastroenterol*. 2020;18(3):476-87.
- Hanafy AS, El Hawary AT, Hamed EF, Hassaneen AM. Impact of *Helicobacter pylori* eradication on refractory thrombocytopenia in patients with chronic HCV awaiting antiviral therapy. *Eur J Clin Microbiol Infect Dis*. 2016;35(7):1171-6.
- Ghaith D, Elzahry M, Mostafa G, Mostafa S, Elsherif R, Ramzy I. Mutations affecting domain V of the 23S rRNA gene in *Helicobacter pylori* from Cairo, Egypt. *J Chemother*. 2016;28(5):367-70.
- Sabah AA, Gneidy MR, Saleh NM. Prevalence of *Helicobacter pylori* infection among adult patients with different gastrointestinal parasites in Tanta City district. *J Egypt Soc Parasitol*. 2015;45(1):101-6.
- Mosbah A, Nabel Y. *Helicobacter pylori*, *Chlamydiae pneumoniae* and *trachomatis* as probable etiological agents of preeclampsia. *J Matern Fetal Neonatal Med*. 2016;29(10):1607-12.
- Hamed ME, Hussein HM, El Sadany HF, Elgobashy AA, Atta AH. Seroprevalence of *Helicobacter pylori* infection among family members of infected and non-infected symptomatic children. *J Egypt Soc Parasitol*. 2013;43(3):755-66.
- El-Eshmawy MM, El-Hawary AK, Abdel Gawad SS, El-Baiomy AA. *Helicobacter pylori* infection might be responsible for the interconnection between type 1 diabetes and autoimmune thyroiditis. *Diabetol Metab Syndr*. 2011;3(1):28.
- El-Masry S, El-Shahat M, Badra G, Aboel-Nour MF, Lotfy M. *Helicobacter pylori* and Hepatitis C Virus Coinfection in Egyptian Patients. *J Glob Infect Dis*. 2010;2(1):4-9.
- El-Nakeeb A, Fikry A, Abd El-Hamed TM, Fouda el Y, El Awady S, Youssef T, et al. Effect of *Helicobacter pylori* eradication on ulcer recurrence after simple closure of perforated duodenal ulcer. *Int J Surg*. 2009;7(2):126-9.
- Hamed SA, Amine NF, Galal GM, Helal SR, Tag El-Din LM, Shawky OA, et al. Vascular risks and complications in diabetes mellitus: the role of *Helicobacter pylori* infection. *J Stroke Cerebrovasc Dis*. 2008;17(2):86-94.
- Badran HM, Mahfouz ME. Cytotoxin-associated gene-A bearing strains of *Helicobacter pylori* and atrial fibrillation due to ischemic origin: is there a link? *Eur J Cardiovasc Prev Rehabil*. 2007;14(4):518-20.
- Elsheikh MN, Mahfouz ME. Prevalence of *Helicobacter pylori* DNA in recurrent aphthous ulcerations in mucosa-associated lymphoid tissues of the pharynx. *Arch Otolaryngol Head Neck Surg*. 2005;131(9):804-8.
- El Miedany YM, Baddour M, Ahmed I, Fahmy H. Sjogren's syndrome: concomitant *H. pylori* infection and possible correlation with clinical parameters. *Joint Bone Spine*. 2005;72(2):135-41.

15. El-Shahat M, El-Masry S, Lotfy M, El-Kenawy Ael M, Nasif WA. Relationship of *Helicobacter pylori* to Bcl-2 family expression, DNA content, and pathological characteristics of gastric cancer. *Int J Gastrointest Cancer*. 2005;36(2):61-8.
16. Elshal MF, Elsayed IH, El Kady IM, Badra G, El-Refaei A, El-Batanony M, et al. Role of concurrent *S. mansoni* infection in *H. pylori*-associated gastritis: a flow cytometric DNA-analysis and oxyradicals correlations. *Clin Chim Acta*. 2004;346(2):191-8.
17. Abdel Mageed LM, Hafez M, El-Hameed AA, Masoud AG, Elbasmy AA. Contribution of hepatitis C virus and *Helicobacter Pylori* co-infection as possible predisposing factors in the occurrence of gastric mucosal dysplasia. *J Egypt Natl Canc Inst*. 2004;16(4):231-6.
18. Gad Elhak N, Abd Elwahab M, Nasif WA, Abo-Elenein A, Abdalla T, el-Shobary M, et al. Prevalence of *Helicobacter pylori*, gastric myoelectrical activity, gastric mucosal changes and dyspeptic symptoms before and after laparoscopic cholecystectomy. *Hepatogastroenterology*. 2004;51(56):485-90.
19. El-Nasr MS, Elibiary SA, Bastawi MB, Hassan A, Shahin Y, Hassan L, et al. Evaluation of a new enzyme immunoassay for the detection of *Helicobacter pylori* in stool specimens. *J Egypt Soc Parasitol*. 2003;33(3):905-15.
20. Bassily S, Frenck RW, Mohareb EW, Wierzba T, Savarino S, Hall E, et al. Seroprevalence of *Helicobacter pylori* among Egyptian newborns and their mothers: a preliminary report. *Am J Trop Med Hyg*. 1999;61(1):37-40.
21. Omar MM, el-Ansary M, Mostafa I, Akl M, el-Sherbini E, el-Badrawy N, et al. *Helicobacter pylori* among Egyptian patients with chronic liver diseases. A comparative study. *J Egypt Soc Parasitol*. 1997;27(2):563-70.
22. Salem OE, Youssri AH, Mohammad ON. The prevalence of *H. pylori* antibodies in asymptomatic young egyptian persons. *J Egypt Public Health Assoc*. 1993;68(3-4):333-52.
23. Salem OE, Thabet TM, El-Deeb SK, Youssri AH. Study of the prevalence of specific human IgG against *H. pylori* among medical personnel. *J Egypt Public Health Assoc*. 1993;68(3-4):309-31.
24. Eskander AE, Mounir BI, Morcos Ghobrial C, El-Karaksy HM. *Helicobacter pylori* infection in children with portal hypertensive gastropathy. *Minerva Pediatr*. 2018;70(4):360-4.
25. Badr MA, El-Saadany HF, Ali AS, Abdelrahman D. Study of *H. pylori* infection in children with recurrent abdominal pain attending the pediatrics outpatient clinic of Zagazig University Hospitals. *J Egypt Soc Parasitol*. 2012;42(3):735-40.
26. Fayed SB, Aref MI, Fathy HM, Abd El Dayem SM, Emara NA, Maklof A, et al. Prevalence of celiac disease, *Helicobacter pylori* and gastroesophageal reflux in patients with refractory iron deficiency anemia. *J Trop Pediatr*. 2008;54(1):43-53.
27. Mohammad MA, Hussein L, Coward A, Jackson SJ. Prevalence of *Helicobacter pylori* infection among Egyptian children: impact of social background and effect on growth. *Public Health Nutr*. 2008;11(3):230-6.
28. El-Mahallawy HA, Bahgat N, El-Din HM, Farag SA, Nouh A, El-Attar I. Hepatitis C virus and its genotypes and *Helicobacter pylori* in pediatric non-Hodgkin's lymphoma: could there be a possible etiologic role? *J Egypt Natl Canc Inst*. 2004;16(2):114-22.
29. Omar AA, Ibrahim NK, Sarkis NN, Ahmed SH. Prevalence and possible risk factors of *Helicobacter pylori* infection among children attending Damanhour Teaching Hospital. *J Egypt Public Health Assoc*. 2001;76(5-6):393-410.